Zevra Therapeutics, Inc. (ZVRA)
(Delayed Data from NSDQ)
$4.60 USD
+0.04 (0.77%)
Updated May 29, 2024 03:59 PM ET
After-Market: $4.59 -0.01 (-0.11%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth A Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ZVRA 4.60 +0.04(0.77%)
Will ZVRA be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for ZVRA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ZVRA
Zevra Therapeutics (ZVRA) Reports Q1 Loss, Lags Revenue Estimates
Esperion Therapeutics (ESPR) Q1 Earnings and Revenues Beat Estimates
ZVRA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Will OptiNose (OPTN) Report Negative Q1 Earnings? What You Should Know
Will Zevra Therapeutics (ZVRA) Report Negative Earnings Next Week? What You Should Know
Alpine Immune Sciences, Inc. (ALPN) Q4 Earnings and Revenues Beat Estimates
Other News for ZVRA
Analysts Offer Insights on Healthcare Companies: Zevra Therapeutics (ZVRA), ALX Oncology Holdings (ALXO) and Quoin Pharmaceuticals (QNRX)
Analysts Are Bullish on Top Healthcare Stocks: Regulus (RGLS), Zevra Therapeutics (ZVRA)
Strong Buy Rating for Zevra Therapeutics Based on Solid Financials and Promising Drug Pipeline
Zevra Therapeutics to Participate at Upcoming Investor Events
Zevra Therapeutics Inc (ZVRA) (Q1 2024) Earnings Call Transcript Highlights: Navigating ...